Monica J. Smith is a medical journalist specializing in gastrointestinal health. She has written extensively for General Surgery News, Clinical Oncology News, and Gastroenterology & Endoscopy News. Given her interest in well-being, it was only natural for her to focus largely on issues related to the digestive system; as Hippocrates noted, good health starts in the gut.
Latest by Monica Smith
Increasing evidence suggests over time, proton pump inhibitors, used to treat symptoms of gastroesophageal reflux disease, may not be as benign as people think.
In recent years, serious, sometimes deadly, infections in people who have undergone endoscopies have drawn media attention and increased scrutiny from the FDA.
Most people with irritable bowel syndrome suffer symptoms like abdominal pain for at least a year before seeing a doctor.
The FDA has approved the first biosimilar drugs to treat inflammatory bowel diseases, such as severe Crohn’s disease and ulcerative colitis.
People with Crohn’s disease are at increased risk for colorectal cancer. Statin drugs to control cholesterol levels may help reduce this risk.
Having inflammatory bowel disease increases your risk for antibiotic-resistant C. Diff bacterial infection and recurrence.
If you’ve lost weight because of functional dyspepsia, or upset stomach, you might be able to gain it back by taking a certain antidepressant.
Drugs known as proton pump inhibitors are usually the first therapy recommended to people with gastroesophageal reflux disease. Surgery is another option.
Recent research concluded that drugs used to treat chronic idiopathic constipation are comparable.